H. Gurney

N. Thatcher, R. Swindell, J. Weiner, 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.

L. Appleman, G. Gravis, E. Yu, 2022, European urology.

Patterns of care and outcomes of men with germ cell tumors in a high‐volume Australian center

A. Hayden, S. Turner, H. Gurney, 2021, Asia-Pacific journal of clinical oncology.

Hypercalcaemia in small cell lung cancer: report of a case associated with parathyroid hormone-related protein (PTHrP).

T. Martin, R. Stuart-Harris, J. Danks, 1993, European journal of cancer.

Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin.

J. Boyages, R. Kefford, H. Gurney, 1998, Australian and New Zealand journal of medicine.

Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres

A. Nagrial, M. Carlino, R. Hui, 2022, Cancer medicine.

Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management *

J. Desai, N. Pavlakis, G. McArthur, 2007 .

S. Culine, M. Climent, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

H. Nishiyama, C. Sternberg, J. Bellmunt, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.

R. Kefford, R. Stuart-Harris, H. Gurney, 1995, European journal of cancer.

KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

A. Tafreshi, J. Bono, S. Oudard, 2020 .

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).

R. Motzer, T. Choueiri, E. Plimack, 2020 .

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.

F. Saad, C. Sternberg, R. Epstein, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma

D. Crowther, M. Ranson, C. H. Buckley, 1990 .

Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma.

D. Crowther, M. Ranson, C. H. Buckley, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

R. Motzer, T. Powles, M. Atkins, 2018 .

A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.

D. Goldstein, M. Tattersall, S. Ackland, 1997, Seminars in oncology.

Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.

D. Goldstein, M. Tattersall, S. Ackland, 1997, Oncology.

Primary treatment of the prostate improves local palliation in men who ultimately develop castrate‐resistant prostate cancer

P. de Souza, H. Gurney, Manish I. Patel, 2013, BJU international.

625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

L. Appleman, G. Gravis, E. Yu, 2020 .

Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4‐month, open‐label study in Australia and New Zealand

H. Gurney, D. Dalley, D. Bell, 2008, Internal medicine journal.

Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

L. Appleman, A. Drakaki, E. Yu, 2019, Journal of Clinical Oncology.

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

L. Appleman, G. Gravis, E. Yu, 2019 .

Updated ef ﬁ cacy results from the JAVELIN Renal 101 trial: ﬁ rst-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

R. Motzer, M. Grimm, M. B. Atkins, 2020 .

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

S. Culine, M. Climent, T. Choueiri, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma

Bohuslav Melichar, Yoshihiko Tomita, Nizar M. Tannir, 2018, The New England journal of medicine.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

C. Porta, M. Burotto, R. Motzer, 2020, ESMO Open.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma

R. Motzer, J. Larkin, T. Choueiri, 2019, The New England journal of medicine.

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

H. Gurney, H Gurney, Howard Gurney, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

R. Motzer, E. Plimack, J. Sosman, 2017, European urology.

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

M. Stockler, L. Horvath, A. Swarbrick, 2017, British Journal of Cancer.

A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer

M. Stockler, P. Meikle, P. Mundra, 2017, International journal of cancer.

Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study

D. Gillatt, F. Rapport, K. Churruca, 2017, BMJ Open.

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

M. Stockler, M. Chatfield, S. Clark, 2014, British Journal of Cancer.

Moving towards dose individualization of tyrosine kinase inhibitors.

J. Schellens, R. Mathijssen, H. Gurney, 2011, Cancer treatment reviews.

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

M. Wiese, A. Rowland, R. Mckinnon, 2017, British Journal of Cancer.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

R. Motzer, T. Choueiri, E. Plimack, 2020, Cancer.

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

A. Ravaud, R. Motzer, T. Choueiri, 2017, European urology.

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214.

C. Porta, R. Motzer, T. Powles, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The management of primary fallopian tube carcinoma

D. Crowther, H. Gurney, D. Murphy, 1990, British journal of obstetrics and gynaecology.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

C. Porta, A. Ravaud, R. Motzer, 2019, The Lancet.

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

M. Borre, T. Pham, Y. Loriot, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical concepts for cabazitaxel in the management of metastatic castration‐resistant prostate cancer

H. Gurney, Loma Al-Mansouri, 2019, Asia-Pacific journal of clinical oncology.

Challenges in the sequencing of therapies for the management of metastatic castration‐resistant prostate cancer

H. Gurney, P. Parente, F. Parnis, 2014, Asia-Pacific journal of clinical oncology.

CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy

C. Clarke, R. Balleine, C. Liddle, 2004, Clinical pharmacology and therapeutics.

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study

A. Zwinderman, Y. Daali, J. Schellens, 2014, Clinical Pharmacokinetics.

Irinogenetics: how many stars are there in the sky?

R. Mathijssen, H. Gurney, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.

D. Dodwell, N. Thatcher, H. Gurney, 1991, European journal of cancer.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2018, British Journal of Cancer.

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.

T. Powles, S. Park, C. Sternberg, 2022, Journal of Clinical Oncology.

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

T. Powles, M. Galsky, S. Park, 2020, The Lancet. Oncology.

Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

T. Powles, G. Sonpavde, J. Rosenberg, 2021 .

Bone metastases in hypernephroma. Frequency of scapular involvement

G. Larcos, H. Gurney, A. Langlands, 1989, Cancer.

High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial

David P. Smith, M. Fenech, V. Gebski, 2021, BMJ Open.

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

M. Tattersall, D. Goldstein, M. Tattersall, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial P aclitaxel I mproves O utcome C ompared W ith C MFP Combination C hemotherapy a s F ront-Line T herapy in U ntreated M etastatic B reast C ancer

D. Goldstein, S. Ackland, J. Dewar, 1999 .

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Rosemary L. Balleine, Georgia Chenevix-Trench, Craig Luccarini, 2018, Scientific Reports.

A Second Australian Family with Hemoglobin North Shore (β134 Val→glu)

H. Gurney, K. Phadke, P. Fleming, 1987 .

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

C. Porta, A. Ravaud, R. Motzer, 2020, Journal for ImmunoTherapy of Cancer.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

C. Porta, R. Motzer, T. Powles, 2019, The Lancet. Oncology.

Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.

D. Ye, Wen‐Cheng Chang, S. Pang, 2014, Clinical genitourinary cancer.

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

M. Burotto, R. Motzer, T. Powles, 2021, Annals of Oncology.

Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

M. Stockler, V. Gebski, M. Chatfield, 2014, Annals of Oncology.

Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.

M. Stockler, N. Pavlakis, S. Clark, 2014 .

Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982-2011.

D. Sabanathan, S. Pearson, S. Turner, 2016, Cancer Epidemiology.

CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

R. Motzer, E. Plimack, J. Sosman, 2015 .

Metformin in prostate cancer: two for the price of one.

M. Wong, H. Gurney, B. Gao, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of a pancreatic tumour secreting parathyroid hormone related protein.

D. Dodwell, H. Gurney, H. Scarffe, 1990, BMJ.

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region

Jae-Lyun Lee, H. Gurney, M. Eto, 2022, Asia-Pacific journal of clinical oncology.

KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.

T. Powles, T. Choueiri, S. Park, 2018 .

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

M. Wiese, A. Rowland, J. Miners, 2017, Expert opinion on drug metabolism & toxicology.

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

I. Kerridge, Peter Shaw, C. Tiley, 2010, British journal of clinical pharmacology.

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.

N. Spry, K. McCaul, L. Kristjanson, 2006, European journal of cancer.

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

C. Porta, M. Burotto, R. Motzer, 2021 .

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

M. Burotto, R. Motzer, T. Powles, 2020 .

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis.

C. Porta, R. Motzer, T. Powles, 2018, Annals of Oncology.

Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews

K. Webber, S. Pearson, H. Gurney, 2020, JNCI Cancer Spectrum.

Developing a new framework for dose calculation.

H. Gurney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft‐versus‐tumour effect

H. Gurney, D. Gottlieb, A. Goodwin, 2007, Internal medicine journal.

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

R. Motzer, T. Powles, M. Atkins, 2020, Clinical Cancer Research.

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

R. Motzer, E. Plimack, J. Sosman, 2015 .

Dose calculation of anticancer drugs.

H. Gurney, B. Gao, H. Klumpen, 2008, Expert opinion on drug metabolism & toxicology.

e‐TC: Development and pilot testing of a web‐based intervention to reduce anxiety and depression in survivors of testicular cancer

M. Stockler, A. Wootten, B. Tran, 2017, European journal of cancer care.

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

K. Webber, S. Pearson, H. Gurney, 2018, BMJ Open.

The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross‐sectional study

M. Stockler, P. Butow, M. King, 2013, Psycho-Oncology.

The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study

M. Stockler, P. Butow, M. King, 2016, Journal of Cancer Survivorship.

Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

H. Gurney, M. Arasaratnam, Loma Al-Mansouri, 2019, European Journal of Hospital Pharmacy: Science and Practice.

Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial.

M. Stockler, V. Gebski, M. Chatfield, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Death of a clinical trial: a speculative inclusion criterion gone wrong

M. Rosenthal, H. Gurney, H. Woo, 2007, Internal medicine journal.

Emerging and second line therapies for the management of metastatic castration‐resistant prostate cancer: The Australian perspective

H. Gurney, P. Parente, F. Parnis, 2012, Asia-Pacific journal of clinical oncology.

Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients.

M. McKay, M. Molloy, M. Thaysen‐Andersen, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

R. Plummer, T. Buclin, M. Rudek, 2023, ESMO open.

Dual‐energy x‐ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy

A. Hayden, S. Turner, H. Gurney, 2023, The Medical journal of Australia.

Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.

T. Powles, S. Park, C. Sternberg, 2022, Future oncology.

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

A. Tafreshi, J. Carles, J. Bono, 2019, Journal of Clinical Oncology.

Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

A. Tafreshi, J. Bono, E. Yu, 2019, Journal of Clinical Oncology.

Nuances to precision dosing strategies of targeted cancer medicines

M. Wiese, A. Rowland, R. Mckinnon, 2020, Pharmacology research & perspectives.

CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).

R. Motzer, E. Plimack, J. Sosman, 2016 .

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2018, British Journal of Cancer.

Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2018 .

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis

S. Park, N. Tsuchiya, Jae-Lyun Lee, 2022, International Journal of Clinical Oncology.

Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.

T. Powles, S. Park, C. Sternberg, 2023, European urology.

698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

T. Powles, G. Sonpavde, J. Rosenberg, 2021, Annals of Oncology.

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC).

R. Motzer, J. Larkin, T. Choueiri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.

C. Porta, M. Burotto, T. Powles, 2021, European urology.

Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

D. van der Poorten, H. Gurney, V. Nguyen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Lacombe, C. Gedye, P. Tomczak, 2022, Annals of Oncology.

Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation

V. Gebski, R. Balleine, R. Kefford, 2013 .

Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

A. Ravaud, R. Motzer, T. Choueiri, 2016 .

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

S. Culine, J. Bernhard, J. Larkin, 2017, European journal of cancer.

Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

J. Bono, L. Appleman, G. Gravis, 2020 .

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Y. Chiew, G. Chenevix-Trench, J. Beesley, 2018, Scientific Reports.

Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.

D. Dodwell, N. Thatcher, H. Gurney, 1993, Annals of Oncology.

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

R. Kim, J. Verweij, A. Sparreboom, 2011, Clinical pharmacology and therapeutics.

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio

R. Mathijssen, P. de Bruijn, N. Wilcken, 2020, Breast.

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

T. Powles, S. Park, C. Sternberg, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.

R. Motzer, T. Powles, T. Choueiri, 2023, Journal of Clinical Oncology.

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

C. Porta, M. Burotto, R. Motzer, 2023, Journal of Clinical Oncology.

Home or Hospital? An Evaluation of the Costs, Preferences, and Outcomes of Domiciliary Chemotherapy

S. Caleo, H. Gurney, P. Harnett, 2000, International Journal of Health Services.

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.

R. Figlin, R. Motzer, M. Ginsberg, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring

V. Gebski, D. Sabanathan, C. Liddle, 2017, Cancer Chemotherapy and Pharmacology.

A cost–utility approach to the use of 5‐fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma

H. Gurney, P. Harnett, P. Souza, 1993, The Medical journal of Australia.

Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

C. Porta, R. Motzer, T. Powles, 2023, Journal of Clinical Oncology.

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

E. Small, D. Rathkopf, D. Olmos, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).

T. Choueiri, E. Plimack, M. Voss, 2022, Journal of Clinical Oncology.

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

M. Climent, L. Lacombe, Chung-Han Lee, 2023, The Lancet Oncology.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

A. Ravaud, R. Motzer, T. Choueiri, 2015, The New England journal of medicine.

Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

E. Small, D. Rathkopf, D. Olmos, 2023, Journal of Clinical Oncology.

Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).

R. Motzer, T. Powles, T. Choueiri, 2016 .

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

T. Powles, S. Park, J. Bellmunt, 2021 .

704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100

T. Powles, S. Radulović, N. Tsuchiya, 2020 .

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, T. Choueiri, D. Bajorin, 2022, Journal of Clinical Oncology.

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

S. Culine, M. Climent, T. Choueiri, 2019, Annals of Oncology.

Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.

T. Powles, M. Climent, E. Plimack, 2022, Journal of Clinical Oncology.

Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study

S. Pearson, H. Gurney, M. Aslam, 2023, The Lancet regional health. Western Pacific.

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

R. Motzer, E. Plimack, J. Sosman, 2018, European Urology.

LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

S. Culine, M. Climent, T. Choueiri, 2017 .

Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2017 .

Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).

R. Motzer, J. Larkin, T. Choueiri, 2017 .

KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

J. Bono, L. Appleman, G. Gravis, 2021 .

RENAL PHOSPHATE THRESHOLD AND RESPONSE TO PAMIDRONATE IN HUMORAL HYPERCALCAEMIA OF MALIGNANCY

R. Kefford, R. Stuart-Harris, H. Gurney, 1989, The Lancet.

Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice

R. Huddart, T. Powles, C. Sternberg, 2021, The Journal of urology.

Racial disparity in metastatic renal cell cancer: The pharmaco‐anthropology of sunitinib

H. Gurney, A. Zhang, 2014, Asia-Pacific journal of clinical oncology.

Transporter pumps and imatinib: A cause of pharmacokinetic resistance?

C. Liddle, H. Gurney, H. Klumpen, 2008, Cancer biology & therapy.

Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2

W. B. Church, Fanfan Zhou, Ling Zhu, 2013, The AAPS Journal.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross‐sectional study

M. Stockler, P. Butow, M. King, 2013, Psycho-oncology.

Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial.

D. Bailey, D. Gillatt, D. Sabanathan, 2019, Journal of Clinical Oncology.

MILGa-01: A first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers.

D. Gillatt, D. Sabanathan, K. Thurecht, 2017 .

Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC).

C. Liddle, H. Gurney, P. Fox, 2014 .

Pharmacogenetic factors predicting the need for a higher dose of imatinib.

J. Schellens, D. Goldstein, R. Mathijssen, 2010 .

Patient Preference or Indifference: Learning from the CABADOC Study.

H. Dhillon, H. Gurney, A. Joshua, 2021, European urology.

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

T. Choueiri, S. Park, T. Buchler, 2023, International journal of cancer.

Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, M. Climent, T. Choueiri, 2018 .

An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer

B. Solomon, I. Davis, M. Rosenthal, 2009, American journal of clinical oncology.

Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2

Fanfan Zhou, Ling Zhu, Jian Zheng, 2013, The AAPS Journal.

Doctor-patient communication: a study of Australian ethnic urological cancer patients

H. Gurney, Manish I. Patel, S. Cerimagic, 2015 .

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

R. Motzer, E. Plimack, J. Sosman, 2017, European urology.

Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients

M. Mclean, A. Hayden, J. Frystyk, 2022, Endocrine connections.

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.

G. Kramer, S. Byun, M. D. De Santis, 2023, Journal of Clinical Oncology.

612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

A. Tafreshi, S. Oudard, G. Gravis, 2021, Annals of Oncology.

A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, F. D. De Braud, D. Geynisman, 2022, Journal of Clinical Oncology.